| Bioactivity | S07-1066 is an aldo-keto reductase 1C3 (AKR1C3) inhibitor, synergizing doxorubicin (DOX) cytotoxicity. S07-1066 selectively blocks AKR1C3-mediated reduction of DOX, and reverses the DOX resistance in overexpressing AKR1C3 cells[1]. |
| Target | AKR1C3 |
| Name | S07-1066 |
| CAS | 876625-29-5 |
| Formula | C16H11Cl2FO2 |
| Molar Mass | 325.16 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. He S, et al. Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment. J Med Chem. 2023 Jul 6. |
S07-1066
CAS: 876625-29-5 F: C16H11Cl2FO2 W: 325.16
S07-1066 is an aldo-keto reductase 1C3 (AKR1C3) inhibitor, synergizing doxorubicin (DOX) cytotoxicity. S07-1066 selectiv
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.